Prodigiosin/celecoxib-loaded into zein/sodium caseinate nanoparticles as a potential therapy for triple negative breast cancer

• Published in: Scientific reports Vol. 14; no. 1; p. 181
• Main Authors: Mohamed, Wafaa A., El-Nekhily, Nefertiti A., Mahmoud, Hoda E., Hussein, Ahmed A., Sabra, Sally A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02-01-2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/45; 631/67; Angiogenesis; Apoptosis; Bioavailability; Breast cancer; Caseins; Celecoxib; Celecoxib - pharmacology; Cytotoxicity; Encapsulation; Female; Humanities and Social Sciences; Humans; Malignancy; multidisciplinary; Nanoparticles; Prodigiosin; Prodigiosin - pharmacology; Science; Science (multidisciplinary); Sodium; Synergism; Triple Negative Breast Neoplasms - drug therapy; Tumor cell lines; Wound healing; Zein
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-50531-4

Nowadays, breast cancer is considered one of the most upsetting malignancies among females. Encapsulation of celecoxib (CXB) and prodigiosin (PDG) into zein/sodium caseinate nanoparticles (NPs) produce homogenous and spherical nanoparticles with good encapsulation efficiencies (EE %) and bioavailability. In vitro cytotoxicity study conducted on human breast cancer MDA-MB-231 cell lines revealed that there was a significant decline in the IC50 for encapsulated drugs when compared to each drug alone or their free combination. In addition, results demonstrated that there is a synergism between CXB and PDG as their combination indices were 0.62251 and 0.15493, respectively. Moreover, results of scratch wound healing assay revealed enhanced antimigratory effect of free drugs and fabricated NPs in comparison to untreated cells. Furthermore, In vitro results manifested that formulated nanoparticles exhibited induction of apoptosis associated with reduced angiogenesis, proliferation, and inflammation. In conclusion, nanoencapsulation of multiple drugs into nanoparticles might be a promising approach to develop new therapies for the managing of triple negative breast cancer.